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mtDNA mutationNARP, are well-established mitochondrial syndromes associated with speciﬁc
point mutations of mitochondrial DNA (mtDNA). However, these recurrent mtDNA mutations account for
only a minority of mitochondrial disease cases. To evaluate the impact of novel mtDNA mutations, we
performed mtDNA sequence analysis in muscle and other tissues of 240 patients with different
mitochondrial neuromuscular syndromes. We identiﬁed a total of 33 subjects with novel, private or
uncommon mutations. Among these, ﬁve novel mutations were found in both paediatric and adult cases. We
here report on the clinical description of these patients, as well as the biochemical and molecular genetic
characterization of the corresponding mutations. Patients 1 and 2 showed changes in ND genes, patient 3
carried a heteroplasmic deletion in the COI gene, patients 4 and 5 carried heteroplasmic mutations in tRNATrp
and tRNAPhe, respectively. Altogether, these data indicate that mtDNA analysis must become part of the
routine screening for mitochondrial disorders.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe clinical spectrum of mitochondrial disorders is extremely
heterogeneous, affecting young and adult patients at any age, with
involvement of a wide variety of tissues. Recent epidemiological
studies assign to the ﬁvemost frequent pathogenicmitochondrial DNA
(mtDNA) mutations a prevalence as high as 1 in 5000 live births [1].
An accurate and complete diagnostic workout is of course
essential, and requires a systematic approach that combines and
integrates clinical investigation and laboratory studies. DNA analysis
and mitochondrial respiratory chain (MRC) assays remain the corner
stones for the diagnosis, but in several instances numerous other skills
and disciplines must concur, not only for the complete elucidation of
the etiology and pathogenesis of a disease entity, but also to formulate
evidence-based predictions about the clinical course and prognostic
outcome.tics, IRCCS Foundation Neuro-
, Italy. Tel.: +390223942633;
ors.
ll rights reserved.Truly enough, some patients present with syndromes that are
strongly suggestive of a mitochondrial disease, but many others have
clinical signs that overlap with those of other disorders. Children in
particular usually show very generic clinical features, so that a host of
laboratory and physiological studies must be planned, including
neuroimaging examination, proton magnetic resonance spectroscopy
(MRS) of brain and/or phosphorus MRS of muscle, neurophysiological
assessment of the central and peripheral nervous systems, and
biomarker search in body ﬂuids. Morphological and biochemical
hallmarks characterize many, albeit not all, of these syndromes. For
instance, the “ragged red” transformation of muscle ﬁbers (RRF) is a
frequent morphological clue, especially in adult patients; RRFs consist
of abnormal mitochondria that accumulate in discrete segments along
the muscle ﬁber, especially near the sarcolemma, eventually causing
the ﬁber to “crack”. Muscle ﬁbers that stain negative to the
histochemical reaction to cytochrome c oxidase (COX, respiratory
complex IV) are also frequently observed in mitochondrial encepha-
lomyopathy, and usually coincide with RRFs. Nevertheless, typical
“mitochondrial” ﬁndings may be absent in otherwise demonstrated
mitochondrial disorders. This is the case for Leber's Hereditary Optic
Neuropathy (LHON), for Neuropathy Ataxia and Retinits Pigmentosa
(NARP), and it is also true in many paediatric cases, for instance, but
not only, Leigh syndrome (LS). In these instances, biochemistry of the
Table 1
Clinical, biochemical and genetic features of 33 patients with mtDNA mutations
Patient Age at
onset
Clinical presentation Skeletal muscle
morphology
Biochemical analysis Affected
gene
Mutation (aminoacid
change)
Reference
1 10 mo LS Normal Reduction CI ND1 3688GNA (p.A128T) Present work
2 7 yrs Ataxia, PEO Normal Normal ND5 13094TNC (p.V253A) Present work
3 36 yrs Myopathy RRFs and COX− ﬁbers Reduction CIV COI 6698delA (p.K265fs271X) Present work
4 54 yrs Myopathy COX− ﬁbers Normal tRNATrp 5567TNC Present work
5 47 yrs Ataxia, PEO, deafness RRFs and COX− ﬁbers Reduction CI, CIII and CIV tRNAPhe 642TNC Present work
6 6 yrs MELAS, retinal dystrophy RRFs Reduction CI ND1 3481GNA(p.E59K) [10]
7 10 mo LS Normal Reduction CI ND1 3697GNA (p.G131S) Mutation already reported
www.mitomap.org
8 10 mo LS Normal Reduction CI ND3 10158TNC (p.S34P) [5]
9 15 mo LS Normal Reduction CI ND3 10191TNC (p.S45P) [5]
10 21 yrs EPC, optic atrophy Normal Reduction CI ND3 10191TNC (p.S45P) [10]
11 7 mo LS Normal Reduction CI ND3 10197GNA (p.A47T) Mutation already reported
www.mitomap.org
12 9 mo LS Normal Reduction CI ND4 11777CNA (p.R340S) [5]
13 32 yrs Ataxia, fragmentary hypnic myoclonus RRFs Reduction CI ND5 13063GNA (p.V243I) [10]
14 6 yrs MELAS RRFs Reduction CI ND5 13513GNA (p.D393N) [48]
15 5 mo LS Normal Reduction CI ND5 13513GNA (p.D393N) [5]
16 13 yrs MELAS Normal Reduction CI ND5 13514ANG (p.D393G) [48]
17 17 yrs MELAS Normal Reduction CI ND5 13514ANG (p.D393G) [48]
18 6 yrs Optic atrophy, Leigh-like syndrome Normal Reduction CI ND5 13514ANG (p.D393G) [5]
19 2 mo LS, sensory-neural deafness Normal Reduction CI ND6 14600GNA (p.P25L) [10]
20 Birth LS Normal Reduction CI ND6 14487TNC (p.M63V) [5]
21 5 mo LS, dilating cardiomyopathy Normal Reduction CI ND6 14487TNC (p.M63V) [10]
22 16 yrs Optic atrophy, ataxia Normal Reduction CI ND6 14487TNC (p.M63V) [10]
23 4 yrs LS COX− ﬁbers Reduction CIV COIII 9537insC (p.Q111fs113X) [18]
24 10 yrs Myopathy RRFs Reduction CI and CIII CYTB 15800CNT (p.Q352X) [49]
25 6 yrs MELAS RRFs and COX− ﬁbers Reduction CI, CIII and CIV tRNALeuUUR 3291TNC [50]
26 51 yrs Myopathy RRFs and COX− ﬁbers Normal tRNALeuUUR 3291TNC Mutation already reported
www.mitomap.org
27 12 yrs Deafness, cognitive impairment RRFs Reduction CI tRNALeuUUR 3291TNC Mutation already reported
www.mitomap.org
28 27 yrs Spastic paraparesis Normal Normal tRNAIle 4284GNA [51]
29 16 yrs Severe encephalopathy Normal Reduction CI and CIV tRNAIle 4290TNC [52]
30 10 yrs Ptosis, myopathy, epilepsy Myopathic changes Reduction CI tRNACys 5814TNC Mutation already reported
www.mitomap.org
31 55 yrs PEO, myopathy RRFs and COX− ﬁbers Normal tRNAAsn 5698GNA [53]
32 45 yrs Motor Neuron Disease-like COX− ﬁbers Reduction CIV tRNASerCUN 7472insC [54]
33 48 yrs PEO, myopathy RRFs Reduction CIII and CIV tRNALeuCUN 12315GNA Mutation already reported
www.mitomap.org
LS, Leigh syndrome; PEO, progressive external ophthalmoplegia; EPC, epilepsia partialis continua; RRF, ragged red ﬁbers; COX−, COX-negative ﬁbers; CI, complex I; CIII, complex III;
CIV, complex IV.
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muscle (sometimes liver) biopsy, in cultured ﬁbroblasts or in both is
often the ﬁrst step that can orient towards the molecular deﬁnition of
a mitochondrial disease.
When a mitochondrial disease is suspected, a crucial decision is
how to investigate the patient in the most efﬁcient, least invasive and
least expensive way. In patients suspected of well-established
conditions, such as LHON,MELAS,MERRF, chronic progressive external
ophthalmoplegia (CPEO), Kearns–Sayre, Pearson and Leigh syn-
dromes, direct genetic analysis is indicated for the detection of point
mutations or large-scale rearrangements of mtDNA. DNA can be
extracted by different sources, for instance from blood, oral swab, or
urine sediment. In several cases, however, analysis ofmtDNA extractedTable 2
RFLP analysis
Patient mtDNA mutation Primers
1 3688 G→A 3629Fw 5′-CCTCTAGCCTAGCCGTTTACTCAATCCT
ND1 3900Rc 5′-GAAGGGGGTTCGGTTGGTCTCTG-3′
2 13094T→C 12906Fw 5′-CCTACACTCCAACTCATGAGACCCA-3
ND5 13310Rc 5′-TGCTAGGTGTGGTTGGTTGATGCCG -
4 5567 T→C 5517Fw 5′-TTAGGTTAAATACAGACCAAGAGCCTT
tRNATrp 5800Rc 5′-TTGCAAATTCGAAGAAGCAGCTTC-3′
5 642T→C 477Fw 5′-CCTCCCACTCCCATACTACT-3′
tRNAPhe 700Rc 5′-TTGCATGTGTAATCTTACTAAGAGCTAAT
Sequences of primers used to detect and quantify the mutations: single nucleotides in boldfrom a muscle biopsy is advisable or mandatory, particularly for
mtDNA mutations that propend to accumulate in post-mitotic tissues
(e.g. large-scale mtDNA rearrangements). Still other patients, who do
not fall in anywell-established clinical entity, do require the systematic
screening of the entiremtDNA genome. This analysismust precede the
eventual screening of a host of nuclear-disease genes involved in
mitochondrial energy defects.
We here report the results of a complete mtDNA analysis
carried out in a cohort of 240 patients suspected of having a
mitochondrial disorder based on clinical or biochemical evaluation,
not classiﬁed in any of the “typical” syndromes. A total of 33/240
patients (14%) did have pathogenic mutations, ﬁve of which were
novel (Table 1).Restriction Enzyme
CTGATCAGGGTGAGCATCAAACTCAAACGAC HgaI/cuts the wild-type sequence
′ AluI/cuts the mutant sequence
3′
CAAAGCCCTCAGTAAGTTGGTA-3′ RsaI/cuts the mutant sequence
NdeI/cuts the wild-type sequence
AGAAAGGCTAGGACCAAACCTATTTGCAT-3′
and underlined are modiﬁed in order to create the speciﬁc restriction site.
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2.1. Fibroblast and cybrid cell cultures
Fibroblast cell lines were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM) suppliedwith 10% fetal calf serum (FCS) at 37 °C in a
5% CO2 atmosphere [2]. Transmitochondrial cybrids were obtained by
polyethylene glycol (PEG) fusion, followed by selection in a uridine-
free medium, as described [3]. Cytoplasts derived from cytochalasin-
treated patients' ﬁbroblasts were fused with a mtDNA-less (ρ°)
derivative of the human osteosarcoma 143B cell line. The absence of
mtDNA in ρ° cell lines, and its presence in transmitochondrial cybrids,
was conﬁrmed by PCR analysis using pairs of primers to amplify the
D-loop region, as described [4].
2.2. Morphological and biochemical analyses
Morphological analysis of skeletal muscle, and biochemical assays
of the individual MRC complexes on muscle homogenate, digitonin-
treated ﬁbroblasts and cybrids were carried out as described [5,6].
Speciﬁc activities of each complex were normalised to that of citrate
synthase (CS), an indicator of the number of mitochondria.
2.3. Sequence, restriction fragment length polymorphism analysis and
single-ﬁber PCR analysis
Molecular analysis was performed on genomic DNA extracted
either from muscle, ﬁbroblasts or other tissues. According to a
standardized protocol [5], the entire mtDNA was PCR-ampliﬁed into
eight overlapping fragments using a set of coupled primers. Each of the
eight fragments was then sequenced, with four different ‘sense’
primers, using a 3100 ABI Prism Automated Sequencer. The presence
and the amount of themutationswere veriﬁed by restriction fragment
length polymorphism (RFLP) analysis of PCR products. Primers and
restriction enzymes used for eachmutation are reported inTable 2. The
single-ﬁber PCR analysis was performed according to Sciacco et al. [7].
2.4. Blue native electrophoresis and in-gel activity assays
The detection of the assembled MRC complexes in isolated
mitochondria was performed using blue native gel electrophoresis
(BNGE) as described [8]. After ﬁrst dimensional (1D) or second
dimensional (2D) electrophoresis, proteins were electroblotted onto
nitrocellulose ﬁlters and sequentially immunostained with speciﬁc
antibodies against complex I subunits NDUFA9 (39 kDa) and NDUFB6
(17 kDa), complex IV subunits I, II, IV, and against SDH subunits,
(30 kDa or 70 kDa) (Molecular Probes, Invitrogen). Immuno-
visualizationwas performed with the ‘ECLWestern-blotting detection
analysis system’ (GE Healthcare, Amersham).
The in-gel activity assay for complex I was performed on 1D-BNGE
as described [9].
2.5. Statistics
The complex I values, normalised with CS activity, in 11 homo-
plasmic cybrids from patient 1 vs. 10 wt cybrids from his mother were
compared using non-paired, two-tail Student's t test. The same was
applied in the analysis of single muscle ﬁbers from patients 4 and 5.
Regression analysis was performed for complex I values vs. hetero-
plasmy percentages measured in cybrid clones from patients 2
(n=15).
2.6. Patients
Since 1990 we have been collecting a total of 4200 DNA samples
from patients with an initial suspect of mitochondrial disease. Thelatter was suggested by (a) Clinical evaluation, based on symptoms
and signs of encephalomyopathy, with or without other clues
including, for instance, elevated levels of lactate in body ﬂuids, and/
or CT/MRI ﬁndings typical of mitochondrial disorders such as MELAS,
Leigh syndrome, Alpers' syndrome, etc.; (b) Morphological and/or
biochemical analysis of skeletal muscle biopsy and/or skin ﬁbroblasts,
compatible with defective respiratory chain; (c) identiﬁcation of
pathogenic mutations associated with mitochondrial defects (e.g. the
mutations responsible of MELAS, MERRF, LHON, NARP, Kearns–Sayre
s., etc); (d) strong suggestion of maternal inheritance; (e) the above
points combined.
Genetic diagnosis was reached in approximately 30% of the cases.
Of the remaining cases, in 240 consecutive individuals the suspect of a
mtDNA defect was strong enough as to justify systematic, sequence-
based analysis of the entire mitochondrial genome. A pathogenic
mutation in mtDNAwas identiﬁed in 33/240 cases (Table 1). In ﬁve of
these 33 positive patients, we found new mtDNA mutations; the
corresponding clinical presentations are hereafter reported.
Patient 1 the only child of unrelated Italian parents, was born after
37 weeks of gestation by cesarean delivery because of maternal
gestosis. The birth weight was 3440 g and the Apgar score was
9-10-10. Three days after birth, he presented with an episode of acute
respiratory distress treated with N-CPAP for 24 h. Laboratory and
instrumental ﬁndings at that time were normal except for a systolic
murmur due to a patent foramen ovalis. At 10 months of age, the
patient had an acute episode of metabolic failure, characterized by
vomiting, pallor and profuse sweating followed by lethargy. Since
then, his clinical conditions worsened progressively with psychomo-
tor regression, impairment of upgaze ocular motility with divergent
strabismus, recurrent episodes of vomiting and tonic seizures with
absence, well controlled by barbituric treatment. A ﬁrst MRI study,
performed at 11 months, showed symmetric signal abnormalities in
the basal ganglia and midbrain (not shown). At 24 months the MRI
showed a progression of the symmetric lesions in the basal ganglia,
and the presence of brain cortex and subcortical white matter
alterations (Fig. 1). Proton magnetic resonance spectroscopy ([H]-
MRS) showed a markedly elevated lactate peak in correspondence to
the T2-weighted abnormal signals, with slight reduction of the NAA
and choline peaks. Both PEVs and BAEPs were abnormal. Serum lactic
acid ranged from 2.75 to 3.34 mmol/L (normal rangeb1.33 mmol/L),
but pyruvic acid levels were normal. The child, now 5 years old has a
spastic tetraparesis, with dystonic postures triggered by external
stimuli, especially at the neck and trunk; sub-continuous myoclonic
jerks at the upper limbs partially controlled by antiepileptic
polytherapy with carbamazepine, clobazam and barbiturates, severe
growth and mental retardation. A muscle biopsy performed at
16 months of age was morphologically normal (not shown).
Patient 2 is an 11-year-old child with onset at 7 years with ataxic–
spastic gait; she later developed CPEO, facial weakness with drooling
and difﬁculty in swallowing, occasional seizures, severe growth and
mental retardation. The clinical course has been downhill, with
progressive worsening of the ataxia and PEO, and hearing loss. PEVs
and BAEPs were both abnormal. At 10 years, the blood lactate was in
the normal range, while it was elevated in the CSF. MRI examinations
showed the presence of abnormal signals in the brainstem, cerebellar
dentate nuclei, and basal ganglia, suggestive of a mitochondrial
encephalopathy. An [H]-MRS of the brain showed the presence of a
lactate peak in the abnormal areas. However, a skeletal muscle biopsy
taken at 7 years of agewas morphologically and biochemically normal
(Table 3).
Patient 3 is a 38-year-old man complaining of muscle pain,
weakness and exercise intolerance with no muscle wasting. He had
one episode of myoglobinuria, with very high levels of serum creatine
kinase (CK). An EMG showed modest myopathic abnormalities. A
muscle biopsy showed the presence of numerous COX-negative ﬁbers
and RRFs (Fig. 2A–C).
Fig. 1. BrainMRI of patient 1. (A, B) MRI performed at 2 years of age. (A) Axial T2-weighted and (B) coronal FLAIR images, showing lesions in the basal ganglia, that involve putamina,
globi pallidi and caudate nuclei. In A, hyperintense lesions are present in the thalami. In B small bilateral signal abnormalities are present in the cortex. (C, D) MRI at 3.5 years of age.
(C) T2-weighted and (D) coronal FLAIR images, showing diffuse and marked brain atrophy which involved also the basal ganglia.
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age, when she started complaining fatigue, muscle weakness, joint
pain, xerostomy and xerophthalmy, and low-grade fever. She also
experienced episodes of dysphagia and ﬂuctuating gait instability.
Because of her clinical features and the laboratory ﬁndings of low-
titer antinuclear antibodies, persistently elevated erythrocyte sedi-
mentation rate (ESR), and high-titer PCR, she was suspected as
having connectivitis and treated with high-dose corticosteroids.
Since the anti-inﬂammatory therapy was of modest if any beneﬁt,
she was re-evaluated for her muscle weakness and gait instability.
Myasthenia Gravis was excluded. Laboratory ﬁndings were all
normal except serum creatinine (1.21 mg/L, n.v. 0.5–0.9), serumTable 3
Mitochondrial respiratory chain activities in patients 1–5
Patient CI CII CIII CIV CV CS
Muscle
1 7.2 19.5 127 165 132 154
2 16.1 16.2 91 141 150 130
3 23.7 18.9 89 91 156 117
4 24.8 20.4 108 261 215 57
5 8.9 31.7 45 65 97 197
Controls' mean±s.d. 18.5±2.8 21.5±3.3 128±20 170±26 155±34 145±33
Fibroblasts
1 7.4 12.6 111 92 85 129
2 21.6 17.3 123 115 76 193
4 15 13.4 158 111 134 92
Controls' mean±s.d. 18.4±3.9 13.5±2.5 108±11 125±19 98±14 150±25
Values are expressed as nmol/min mg of protein and normalised with citrate synthase
(CS) activity. Fibroblasts from patient 3 and 5 were not available. CI, complex I; CII,
complex II; CIII, complex III; CIV, complex IV; CV, complex V.CK (195 U/L, n.v. 24–150), ESR (60 mm/h, n.v. 0–20). A muscle CT
scan showed moderate adipose substitution of paravertebral
muscles and bilateral atrophy of ileo-psoas muscles. A muscle
biopsy of the left quadriceps revealed the presence of numerous
COX-negative ﬁbers with a few pre-RRF and lipid storage in some
ﬁbers (Fig. 2D–F).
Patient 5 is a 65-year-old woman with moderate mental retarda-
tion, who developed in her ﬁfties a syndrome characterized by PEO,
muscle weakness with proximal wasting, especially in the upper
girdle and neck district, gait ataxia, peripheral neuropathy, urinary
incontinence, hearing loss and neurosensory deafness. The deep
tendon reﬂexes were absent with reduced vibratory sensation. She
was dysmetric in both upper and lower limbs, and had a positive
Romberg sign and gait ataxia. Amuscle biopsy showed the presence of
numerous COX-negative and RRFs (Fig. 2G–I). Analysis of the POLG1
genewas negative. Family history is negative for neurodegenerative or
neurometabolic disorders.
3. Results
3.1. Biochemical assays
Biochemical assay of MRC revealed the presence of speciﬁc and
isolated complex I deﬁciency in both muscle (39%) and ﬁbroblasts
(40%) of patient 1, while an isolated defect of complex IV (53%) was
detected in the muscle of patient 3. Patient 5 presented with multiple
defects of the MRC complexes I, III and IV (Table 3). However, MRC
activities were normal in both muscle and cultured ﬁbroblasts of
patients 2 and 4 (Table 3). The ﬁbroblasts of patient 3 and 5 were not
available.
Fig. 2. Histochemical analysis in patient 3, 4 and 5 (respectively P3, P4, P5). P3: (A) Cytochrome c Oxidase (COX) stain; (B) NADH Dehydrogenase stain; (C) Modiﬁed Gomori
trichrome stain. P4: (D) COX stain; (E) COX and Succinic Dehydrogenase (SDH) stain; (F) NADH Dehydrogenase stain. P5: (G) COX stain; (H) NADH Dehydrogenase stain; (I)
Modiﬁed Gomori trichrome stain. Serial sections show COX-negative RRF (asterisks). COX activity is diffusely reduced in patient 3, numerous COX-negative RRF are present in patient
5, while only few COX-negative ﬁbers are present in patient 4.
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The sequence analysis of entire mtDNA revealed that patient 1
carried a homoplasmic 3688GNA transition in ND1 gene, causing an
alanine to threonine change in a highly conserved residue (p.A128T)
of the protein (Fig. 3A). Themutation is homoplasmic inmuscle, blood
lymphocytes and ﬁbroblasts, while his mother did not carry the
mutation in blood lymphocytes and in ﬁbroblasts (not shown).
Patient 2 showed the presence of the 13094TNC mutation in the
ND5 gene, that causes a valine to alanine change in a highly conserved
residue (p.V253A) of the protein (Fig. 3B). The mutation was
heteroplasmic in skeletal muscle (50%), lymphocytes (40%) and
ﬁbroblasts (30%) of the patient, while it was absent in the lymphocytes
of her mother, her maternal aunt and two uncles (not shown).
Patient 3 had a single nucleotide deletion, 6698delA in the COI
gene, causing a sequence frame shift of COX I subunit with the
formation of a premature stop codon at aminoacid position 271 and
the production of a truncated protein (p.K265fs271X) (Fig. 3C). The
mutationwas heteroplasmic in muscle (70%) and in urinary epithelial
cells (15%), while it was absent in myoblasts and in maternal
lymphocytes (not shown).
Patient 4 harboured a heteroplasmic 5567TNC mutation (Fig. 3D)
in mt-tRNATrp, that destroys a base pair in the TΨC stem of the tRNA
secondary structure. This mutation was heteroplasmic in muscle
(50%), ﬁbroblasts (30%) and urinary epithelial cells (40%) (not
shown). A sister had no mutation in blood lymphocytes; no other
relatives could be investigated.
Finally, patient 5 carried a 642TNC transition (Fig. 3E) in mt-
tRNAPhe, that destroys a base pair in the aminoacyl acceptor stem. Themutation was heteroplasmic in skeletal muscle (80%), whilst neither
other tissues nor other family members were available for this patient
(not shown).
None of these ﬁve mutations was found in a series of 300 conse-
cutive control DNA samples.
3.3. Biochemical studies on cybrids
To establish the pathogenic role of the two novel ND gene
mutations, we generated transmitochondrial cybrids obtained from
ﬁbroblast cell lines. Since in patient 1 the mutationwas homoplasmic,
we compared cybrids derived from this patient with cybrids derived
from his homoplasmic wild-type mother. The mean activity of
complex I, normalised to that of CS, was 4.0±1.5 in the homoplasmic
mutant clones vs. 17.0±4.0 in the maternal homoplasmic wild-type
clones (Student's t-test p=8.17E−09) (Fig. 4A). For patient 2, we
analysed a series of 15 cybrids with different percentages of
heteroplasmy. As shown in Fig. 4B, the complex I/CS activity ratio
was highly correlated with the percentage of the mutation. These data
clearly demonstrate that the mutations in ND1 and ND5 genes are
indeed responsible for the complex I deﬁciency detected in patients 1
and 2 respectively.
3.4. BNGE analysis of complex I and in gel activity
In order to understand whether the novel ND1 and ND5 gene
mutations interfere with the assembly and amount of complex I, we
performed 1D- and 2D-BNGE on protein derived from ﬁbroblasts of
patient 1, and from two cybrid clones harbouring different percentages
Fig. 3. Mutation analysis in patients 1–5. (A) Sequence analysis of mtDNA in patient 1; top panel: electropherogram of the ND1 gene showing the 3688GNA transition (p.A128T
substitution); bottom panel: multiple alignment of the mutation-containing ND1 region in different species: a red box indicates the mutated aminoacid. (B) Sequence analysis of
mtDNA in patient 2; top panel: sequence of the ND5 gene regionwith the 13094TNC transition (p.V253A substitution); bottom panel: multiple alignment of the mutation-containing
ND5 region in different species; a red box indicates the mutated aminoacid. (C) Sequence analysis of muscle mtDNA in patient 3 after subcloning in suitable vector; top panel: wild-
type COI sequence; bottom panel: mutant COI sequence with a 6698A deletion (p.K265fs271X). (D) Electropherogram of the mtDNA tRNATrp from patient 4, showing the 5567TNC
transition. (E) Sequence analysis of mtDNA tRNAPhe from patient 5, showing the 642TNC transition.
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#13), and 80% heteroplasmic mutant (Clone #6).
Complex I was immunodetected by using antibodies against the
subunit NDUFB6 (17 kDa), that is part of the membrane arm of
complex I, and the 39 kDa subunit NDUFA9, which is located in the
peripheral arm, but very close to the membrane arm.
Western-blot (WB) analysis on 1D-BNGE in ﬁbroblasts of patient 1
demonstrated a strong reduction in the amount of cross reacting
material (CRM) corresponding to the bona ﬁde fully assembled
complex I, using both NDUFB6 and NDUFA9 antibodies, as compared
to control ﬁbroblasts (Fig. 5A). As for patient 2, using the NDUFB6
antibody, cybrid Clone #6 (80% mutant) showed, in addition to fully
assembled Complex I, the accumulation of a lower molecular weight
band, which was absent in cybrid Clone #13 (100% wt). The
anomalous band was not evident using the NDUFA9 antibody (Fig.
5B). Furthermore, by complex I-speciﬁc in-gel activity a clear
reduction of complex I activity was detected in both ﬁbroblasts frompatient 1 and patient 2 (Fig. 5C). Abnormal assembly and function of
CI-containing supercomplexes due to the ND1 or ND5 mutations
cannot be excluded and could indeed lead to the OXPHOS impairment
of these conditions; future work is warranted to demonstrate it.
The assembly of complex I was further investigated byWB analysis
on 2D-BNGE. In ﬁbroblasts from patient 1, the antibody against
subunit NDUFB6 (17 kDa) showed the presence of fully assembled
complex I, although its amount was strongly reduced as compared to
the control (Fig. 6A). Since identical amounts of the very same
samples were used in 1D- and 2D-BNGE, normalization of the protein
loading was performed only in the ﬁrst dimension, by using the
antibody against the 70 kDa SDH subunit (see Fig. 5A).
In mutant cybrid Clone #6 of patient 2, NDUFA9 (39 kDa) cross-
reacting material (CRM) was present only in a position corresponding
to fully assembled complex I. However, NDUFB6 CRMwas also found in
lowmolecular weight (MW) complexes in the 600–270 kDa range (Fig.
6B), representing partially assembled complex I species. Normalization
Fig. 4. Genotype-to-phenotype correlation in patient 1 (A) and patient 2 (B) transmitochondrial cybrids. (A) Complex I activity in homoplasmic cybrids of patient 1 (P1, n=11) vs.
homoplasmic wt clones from his mother (M, n=10). Student's t-test p=8.17E−09. (B) Complex I activity vs. percentage of heteroplasmy in cybrids (n=15). R2=squared
correlation coefﬁcient by linear regression analysis.
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complex II, using an anti-SDH antibody on the same ﬁlters. Complex II
speciﬁc CRMwas similar in cybrid Clone #6 and Clone #13 from patient
2, thus indicating a speciﬁc complex I abnormality (Fig. 6B).
3.5. Studies on COX
To verify the presence and amount of COX subunits in muscle of
patient 3, we performed WB analysis of COX subunits I, II and IV inFig. 5. Complex I assembly state and in-gel activity assays in patient 1 and patient 2. (A) 1D
(B) 1D-BNGEWB analysis of patient 2 cybrids. Clone #13 is wild type, while clone #6 is 80% h
antibodies against the NDUFB6 (17 kDa) and the NDUFA9 (39 kDa) subunits. Antibodies agai
(C) In-gel activity of complex I on one-dimension blue-native gel electrophoresis (1D-BNGE)
show a less intense complex I-speciﬁc band compared to control. Molecular weight (Mk) amitochondrial protein extracts separated by denaturing SDS-PAGE. As
predicted by the COI mutation load detected in skeletal muscle
(approximately 70%), the CRM amount for COX I was markedly
reduced in the patient's sample compared to a control sample. The
reduction is estimated to be approximately 20% by densitometric
analysis and using the intensity of the band detected with SDH
antibody for normalisation (Fig. 7A). In the samewaywe evaluated the
partial reduction for COX II and COX IV, 41% and 45% respectively (Fig.
7B). Unfortunately, muscle was no longer available for further studies.-BNGE WB analysis of mitochondria from ﬁbroblasts of patient 1 (P1) and control (C).
eteroplasmic for the 13094TNCmutation inND5. Complex I was immunovisualized using
nst the 70 kDa (A) or the 30 kDa (B) subunit of complex II were used for normalisation.
of ﬁbroblast extracts from a control (C), patient 1 (P1), and patient 2 (P2). Both patients
re in kDa.
Fig. 6. Immunodetection of complex I assembly intermediates in patient 1 and patient 2. (A) 2D-BNGEWB of patient 1 (P1) and control (C) ﬁbroblasts. The amount of loaded samples
is the same as in the 1D-BNGEWB analysis of Fig. 5. Patient 1 shows decrease in the steady-state levels of complex I holoenzyme detected by an anti-NDUFB6 (17 kDa) antibody. (B)
2D-BNGE WB of patient 2 cybrids. Samples and antibodies are the same as in the experiment shown in Fig. 5. Similar to results in Fig. 5, clone #6 shows an additional sub-assembly
intermediate in the 600 kDa range detected by the anti-NDUFB6 (17 kDa) antibody. To normalize for the amount of loaded proteins, the same ﬁlter was hybridized with an anti SDH
(30 kDa) antibody. Arrows indicate the direction of the electrophoretic runs in the ﬁrst (1D) and second (2D) dimensions.
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To establish the pathogenic role of the two novel mt-tRNA
mutations found in patients 4 and 5, we performed single-ﬁber PCR
analysis in muscle sections stained for COX.
Results obtained in the tRNATrp mutant muscle sample (patient 4)
show a signiﬁcantly higher meanmutant load in COX-negativemuscle
ﬁbers (95%, n=4) than in COX-positive ﬁbers (29%, n=10) (Student's
t test p=2.75E−07) (Fig. 8A). Likewise, the mean mutant load in
COX-negative muscle ﬁbers of patient 5, carrying the tRNAPheFig. 7.Western blot analysis in patient 3. (A) Western blot analysis in patient 3 (P3) and
control (C) skeletal muscle. Loaded samples correspond to 40 μg of total protein. Levels
of the COX I, COX II and COX IV proteins were quantiﬁed byWB immunodetection, using
speciﬁc antibodies against the corresponding polypeptides. SDH (30 kDa) immunode-
tection was used for normalisation. (B) Graphic representation of densitometric
analysis of COX I, II, and IV of patient 3 vs. control samples.mutation, was higher (97%, n=8) than in COX-positive ﬁbers (40%,
n=7) (Student's t test p=2.89E−04) (Fig. 8B).
These data strongly suggest a pathogenic role of both mutations.
4. Discussion
Among the 33/240 consecutive patients (14%) presenting with
known, novel, private or uncommon mtDNA mutations (Table 1), 28
were reported or found to have an already described mutation: 17/28
patients (61%) presented with mutations in ND coding genes (see
Table 1 for the references), 9/28 (32%) had mutations in tRNA genes
(references in Table 1), while the remaining 7% hadmutations in other
protein-coding genes.
Of the ﬁve patients carrying novel mtDNA mutations, those with
mutations in ND1 and ND5 genes were children, while the remaining
three, with mutations in COI, mt-tRNATrp and mt-tRNAPhe, were
adults. Interestingly, no evidence of transmission by descent was
obtained in the three mutations for which the mothers of the patients
could be investigated, although the absence of mtDNA mutations in
blood lymphocytes does not exclude the possibility that other tissues,
notably oocytes, could carry them. Patient 1 carried a novel
homoplasmic mutation in ND1 that was associated with a strong
reduction of complex I activity in both muscle and ﬁbroblasts. Patient
2 carried a heteroplasmic mutation in ND5, which was associated with
a milder biochemical phenotype. In both cases, results on cybrids
clearly demonstrated the pathogenic role of the mutations.
By studying speciﬁc mutations affecting mtDNA-ND subunits,
several progresses have been made in the comprehension of their role
in the assembly/stability of the complex. For instance, ND1, ND4 and
ND6 are essential for the assembly of CI, since their mutations are
associated with markedly reduced levels of fully assembled holoen-
zyme [10,11]. Mutations in ND2 are also associated with altered
assembly demonstrated by accumulation of CI intermediates [12,13].
Somemutations in ND3 and ND5 did affect the enzymatic activity of CI
but not its assembly status [10,14].
In our patients, the reduction in complex I activity on ND1mutant
ﬁbroblasts was paralleled by an akin decrease in the steady-state
levels of the complex I holoenzyme content, as shown by both 1D- and
2D-BNGE WB analysis, while in ND5 mutant cybrids the amount of
complex I was comparable to that of wild-type cybrids (Figs. 5 and 6).
However, the ND5mutation was associated with accumulation of low
MW protein species that were detected by an antibody against the
membrane-arm NDUFB6 subunit, but not by an antibody against the
peripheral-arm NDUFA9 subunit. These results are in agreement with
Fig. 8. Single-ﬁber PCR analysis from skeletal muscle of patient 4 and patient 5. (A)
Correlation between the percentage of heteroplasmic mutation in COX-positive (COX+,
n=10) and COX-negative (COX−, n=4) single ﬁbers from patient 4 (Student's t-test
p=2.75E−07). (B) Correlation between the percentage of heteroplasmic mutation in
COX-positive (COX+, n=7) and COX-negative (COX−, n=8) single ﬁbers from patient
5 (Student's t test p=2.89E−04). Bars show the means.
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last ND subunit to be incorporated into the membrane arm [15], it is
likely not essential for the assembly of the other mtDNA-ND subunits
into the complex. However, 2D-BNGE analysis demonstrated that the
loss of ND5 is associated with instability of the membrane arm, as also
reported by Chomyn [16]. Taken together, the results published by
others, as well as previous data from our own laboratory and the
ﬁndings reported in the present work, suggest that, irrespective of the
particular ND subunit affected, some mutations may compromise
catalysis but not assembly, while others, probably the majority, do
affect both. This is not surprising considering that all ND subunits are
essential for function and form the main protein backbone of the
membrane arm of Complex I.
Patient 3 carries a heteroplasmic deletion of a single nucleotide in
the COI gene that creates a premature stop codon and predicts the
synthesis of a truncated protein lacking the 243/513 aminoacid
residues on the carboxy-terminus. In contrast with ND mutation, just
a handful of mutations have been reported in mtDNA CO genes have
been reported as pathogenic (www.mitomap.org) by affecting the
assembly/stability of Complex IV [17,18]. In particular, the following
COI mutations are known: (i) two missense mutations in patients
with idiopathic sideroblastic anemia [19]; (ii) an out-of-framemicrodeletion in a patient with motor neuron disease [20]; (iii) a
stop codon mutation in a patient with multisystem disorder [17]; (iv)
amissensemutation in a girl with epilepsia partialis continua [21]; (v)
a missense mutation in a patient with cardioencephalopathy [22]; and
ﬁnally (vi) two different nonsense mutations in two patients virtually
identical to our own, that is, affected by a myopathy with exercise
intolerance, muscle pain, myoglobinuria and high levels of CK [23,24].
Additional features in common among the three patients were (i) the
presence of numerous COX-negative ﬁbers and RRFs in the muscle
biopsy (Fig. 2); (ii) an isolated reduction of complex IV activity in the
muscle; (iii) absent or very low mutation load in extra-muscular
tissues; (iv) no mutation found in maternal relatives. Notably, the
patient reported by Kollberg et al. [24] carried a mutation predicting a
premature stop codon at position 269, which is only two codons
upstream from the mutant stop codon of our patient 3. Similar to our
patient, WB analysis in this patient showed reduced levels of COX
subunits I, II and IV (Fig. 7). COX I is the ﬁrst subunit to be inserted in
the inner mitochondrial membrane during COX assembly, followed by
incorporation of COX IV and COX II. Our results and those by Kollberg
et al. indicate that a reduction in the amount of intact COX I is
associated with a parallel reduction in the steady state levels of the
other early-assembly subunits, suggesting that all three subunits are
part of an assembled COX, while mutant, truncated COX I species is
unable to drive the incorporation of the other subunits into the
nascent COX holoenzyme, thus inducing their degradation. Unfortu-
nately, lack of material prevented us to further investigate this point
by performing BNGE on muscle homogenate. Furthermore the COI
mutation failed to be detected in myoblasts of both our patient 3 and
the patient reported by Kollberg et al. [24], despite the high mutant
load found in mature skeletal muscle. Lack of mutation in satellite
muscle cells has previously been reported alsowith another COX point
mutation [25] and with several tRNA [26,27] and cytochrome b
mutations [28]. Mutation heteroplasmy, tissue-speciﬁcity, and, possi-
bly, vigorous induction of mitochondriogenesis, can also explainwhy a
potentially fatal mutation was associated with isolated, adult onset,
relatively benign myopathy. The absence of the mutation in satellite
cells has potential therapeutic implications, making this patient
eligible for treatment based on exercise-training protocols [29,30].
Mitochondrial human disorders are caused by dysfunction of the
OXPHOS system and many of them are associated with altered
assembly of one or more of the OXPHOS system components. The
study of the assembly defects in patients has been useful to unravel
and/or complete the understanding of the processes by which these
large multimeric complexes are formed and to classify patients on the
basis of an altered assembly pattern. In addition, the respiratory chain
is organized, at least in part, as supra-molecular structures in which
the individual complexes of the respiratory chain interact with each
other, giving rise to the so-called respirasomes [31]. In mammalian
mitochondria, almost all CI is assembled into supercomplexes
containing monomeric CI, dimeric CIII and up to four COX complexes
(I1III2IV0–4). Analysis of supercomplex assembly in pathological
conditions, for example in the patients reported in this paper, would
add more information on the functional relevance of these super-
complexes and on the role that mtDNA encoded subunits play in this
process.
Numerous mutations in mitochondrial tRNA genes have been
described in association with diverse clinical phenotypes. Some tRNA
genes, such as the tRNALeu(UUR) and tRNALys genes are more frequently
affected than others [32].
In particular, mutations in tRNATrp gene have been found only in 5
patients affected by a wide range of different clinical presentations
including: MILS [33], spinocerebellar ataxia with neurosensorial
deafness [34], late-onset mitochondrial myopathy [35,36], gastro-
intestinal pseudo-obstructions [37], and dementia with chorea [38].
We identiﬁed a novel mtDNA pointmutation, a 5567TNC in the tRNATrp
gene, in a 68 year-old woman presenting with fatigability, mild
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activities in muscle and ﬁbroblasts were normal, possibly because the
mutation load in both tissues were not particularly high (50% and 30%
respectively); nevertheless, single-ﬁber PCR analysis on COX-positive
vs. COX-negative ﬁbers clearly demonstrated the pathogenic role of
5567TNC.
A total of seven different mutations in the tRNAPhe have been
reported, associated with phenotypes as diverse as tubulointerstitial
nephritis and stroke [39], mitochondrial myopathy [40–42], acute
rhabdomyolysis [43], exercise intolerance and deafness [44], MELAS
[45], and MERRF [46]. Here we report an eighth point mutation in
tRNAPhe in a 65-year old woman presenting with a phenotype
characterized by mental retardation, ataxia, bilateral neurosensory
deafness and peripheral neuropathy. The muscle biopsy presented
numerous RRFs and COX-negative ﬁbers. The mutation fulﬁlls
accepted criteria for pathogenicity, since it occurs at a highly
conserved position within the tRNAPhe gene, suggesting selective
constraint of the wild-type nucleotide at this position. Accordingly,
the mutation disrupts a conserved Watson–Crick T–A base pairing
within the aminoacyl acceptor stem of the tRNA, thus potentially
impairing the stability of the acceptor stem hairpin structure.
From a clinical and diagnostic standpoint, this work demonstrates
that sequence analysis of the entire mtDNA is mandatory in all cases
with a suspect of mitochondrial aetiology, even if not all the clinical
and diagnostic criteria are fulﬁlled. This recommendation is further
corroborated by the recent evidence that mutations of mtDNA are far
more frequent in the general population than previously suspected,
and that mutation load and reduced penetrance plays a crucial role in
the clinical manifestation not only of homoplasmic mutations such as
those associated with LHON, but also of several, perhaps most, of the
heteroplasmic mtDNA mutations as well [47]. It is also noteworthy to
observe that most of the mutations in our cohort hit structural genes
belonging to complex I, while mutations in genes coding for other
structural subunits are much rare, even after normalisation by the
amount of mtDNA sequence encoding for each complex. This suggests
that the selective constraints vary widely among the different MRC
complexes. By the same token, we also found a high percentage of
mutations (32%) in tRNA coding genes, while no mutations in
ribosomal RNA (rRNA) genes were identiﬁed. This observation
suggests either reduced selective stringency for ND- and tRNA-
encoding gene variations, or that mutations in other mtDNA genes or
region are indeed so deleterious to cause embryonic lethality.
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